Wal-Mart Faults Science In Supplement False Ad Suit

Law360, New York (October 28, 2013, 5:31 PM EDT) -- Wal-Mart Inc. on Friday bashed a putative class action alleging consumer deception in the labeling of its Equate-brand heart health supplement, saying the claims rest on clinical testing methods and voluntary industry standards explicitly disowned by federal regulators.

The retailer argued that plaintiff Thamar Sanstisteban Cortina can’t prevail on claims over its statements promoting coenzyme Q10 supplement product Equate CoQ10 as “high absorption" and promising “3 times better absorption” than its competitors because the testing in support of her suit measured "dissolution” and “disintegration.”

Those testing...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.